FEXARAMINE
|
|
|
- CAS号:
- 574013-66-4
- 英文名:
- Fexaramine
- 英文别名:
- CS-1691;Depasan;Actospar;Fexaramine;3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-pr;(E)-methyl 3-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;(E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;Methyl (E)-3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;Methyl (E)-3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester
- 中文名:
- FEXARAMINE
- 中文别名:
- FEXARAMINE,受体(FXR)激动剂;3-[3-[(环己基羰基)[[4'-(二甲基氨基)[1,1'-联苯]-4-基]甲基]氨基]苯基]-2-丙烯酸甲酯;(E)-3-(3-(N-((4'-(二甲基氨基)-[1,1'-联苯]-4-基)甲基)环己烷甲酰胺基)苯基)丙烯酸甲酯;(E)-3-(3-(N-((4'-(二甲基氨基)-[1,1'-联苯]-4-基)甲基)环己烷甲酰胺基)苯基)丙烯酸甲酯;3-[3-[(环己基羰基)[[4\'-(二甲基氨基)[1,1\'-联苯]-4-基]甲基]氨基]苯基]-2-丙烯酸甲酯, >98%
- CBNumber:
- CB31074393
- 分子式:
- C32H36N2O3
- 分子量:
- 496.64
- MOL File:
- 574013-66-4.mol
|
|
|
FEXARAMINE化学性质
-
沸点:
-
677.7±55.0 °C(Predicted)
-
|
-
密度:
-
1.158±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
DMSO : 50 mg/mL (100.68 mM; Need ultrasonic)
-
|
-
酸度系数(pKa):
-
4.95±0.24(Predicted)
-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to beige
-
|
FEXARAMINE性质、用途与生产工艺
Fexaramine是一种有效的、选择性farnesoid X receptor (FXR)激动剂，EC50为25 nM。它对hRXRα, hPPARα, hPPARγ, hPPARδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ和hVDR受体没有活性。
| Target | Value |
FXR
()
|
25 nM(EC50)
|
Bile acid treatment is performed in HuTu-80 cells with Fexaramine (5, 25, and 50 μM) for 24 h. Fexaramine (50 μM) increases small heterodimer partner (SHP) transcript levels by 2.1-fold. The cells are treated with various concentrations of Fexaramine, and the endogenous secretin transcript levels are significantly reduced (33% in 50 μM Fexaramine). Fexaramine treatment also significantly suppresses secretin promoter activity by 32%.
Fexaramine treatment of DIO mice produces a striking metabolic profile that includes reduced weight gain, decreased inflammation, browning of WAT and increased insulin sensitization.
FEXARAMINE
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-10912 | Fexaramine | | 5 mg | 750元 |
| 2024/01/25 | HY-10912 | FEXARAMINE
Fexaramine | 574013-66-4 | 10mg | 1200元 |
574013-66-4, FEXARAMINE 相关搜索:
- Inhibitors
- 合成有机化合物配体
- 标准品
- 小分子抑制剂，天然产物
- 小分子抑制剂
- C32H36N2O3
- (E)-3-(3-(N-((4'-(二甲基氨基)-[1,1'-联苯]-4-基)甲基)环己烷甲酰胺基)苯基)丙烯酸甲酯
- FEXARAMINE,受体(FXR)激动剂
- (E)-3-(3-(N-((4'-(二甲基氨基)-[1,1'-联苯]-4-基)甲基)环己烷甲酰胺基)苯基)丙烯酸甲酯
- 3-[3-[(环己基羰基)[[4\'-(二甲基氨基)[1,1\'-联苯]-4-基]甲基]氨基]苯基]-2-丙烯酸甲酯, >98%
- 3-[3-[(环己基羰基)[[4'-(二甲基氨基)[1,1'-联苯]-4-基]甲基]氨基]苯基]-2-丙烯酸甲酯
- 574013-66-4
- Methyl (E)-3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
- Methyl (E)-3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
- (E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
- Depasan
- Actospar
- 2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-, methyl ester, (2E)-
- CS-1691
- 3-[3-[(Cyclohexylcarbonyl)[[4\'-(dimethylamino)[1,1\'-biphenyl]-4-yl]methyl]amino]phenyl]-2-Propenoic acid methyl ester, >98%
- 3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-pr
- (2E,4Z)-5-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecarboxamido)phenyl)-4-(methoxycarbonyl)penta-2,4-dienoic acid
- (E)-methyl 3-(3-(N-((4'-(dimethylamino)biphenyl-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate
- 2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)[[4'-(diMethylaMino)[1,1'-biphenyl]-4-yl]Methyl]aMino]phenyl]-, Methyl ester
- 3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester
- Fexaramine